Citation
Ilyina, Natalia I., et al. "Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results From Russia." International Archives of Allergy and Immunology, vol. 178, no. 3, 2019, pp. 255-263.
Ilyina NI, Edin AS, Astafieva NG, et al. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. Int Arch Allergy Immunol. 2019;178(3):255-263.
Ilyina, N. I., Edin, A. S., Astafieva, N. G., Lopatin, A. S., Sidorenko, I. V., Ukhanova, O. P., & Khanova, F. M. (2019). Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia. International Archives of Allergy and Immunology, 178(3), 255-263. https://doi.org/10.1159/000494507
Ilyina NI, et al. Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results From Russia. Int Arch Allergy Immunol. 2019;178(3):255-263. PubMed PMID: 30677766.
TY - JOUR
T1 - Efficacy of a Novel Intranasal Formulation of Azelastine Hydrochloride and Fluticasone Propionate, Delivered in a Single Spray, for the Treatment of Seasonal Allergic Rhinitis: Results from Russia.
AU - Ilyina,Natalia I,
AU - Edin,Anton S,
AU - Astafieva,Natalia G,
AU - Lopatin,Andrey S,
AU - Sidorenko,Irina V,
AU - Ukhanova,Olga P,
AU - Khanova,Fatimat M,
Y1 - 2019/01/24/
PY - 2018/05/04/received
PY - 2018/10/12/accepted
PY - 2019/1/25/pubmed
PY - 2019/6/1/medline
PY - 2019/1/25/entrez
KW - Allergic rhinitis
KW - Azelastine
KW - Fluticasone propionate
KW - Intranasal
KW - MP-AzeFlu
KW - Moderate-to-severe rhinitis
KW - Russia
KW - Seasonal
SP - 255
EP - 263
JF - International archives of allergy and immunology
JO - Int Arch Allergy Immunol
VL - 178
IS - 3
N2 - BACKGROUND: The novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a single spray (MP-AzeFlu) was compared with a first-line intranasal antihistamine spray (AZE) in Russian seasonal allergic rhinitis (SAR) patients. METHODS: Moderate-to-severe SAR/rhinoconjunctivitis patients (n = 149; aged 18-65 years) were randomized to receive MP-AzeFlu (137/50 μg AZE/FP per spray) or AZE (137 μg/spray), both as 1 spray/nostril twice daily, in a multicenter, open-label, 14-day, parallel-group trial. The primary outcome was change from baseline in morning and evening reflective total nasal symptom score (rTNSS). Secondary end points included: change from baseline in reflective total ocular symptom score (rTOSS), reflective total of 7 symptom scores (rT7SS), 28-item Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) overall score, and EuroQol-5D (EQ-5D) questionnaire score. RESULTS: When compared with AZE-treated patients, those treated with MP-AzeFlu experienced significantly greater reductions in rTNSS (difference: -2.47; 95% confidence interval [CI] -3.65 to -1.30; p < 0.001), rTOSS (difference: -1.62; 95% CI -2.32 to -0.92; p < 0.001), and rT7SS (difference: -4.34; 95% CI -5.98 to -2.70; p < 0.001). Superior relief observed on day 2 with MP-AzeFlu versus AZE was sustained throughout the study. MP-AzeFlu-treated patients experienced a greater improvement in QoL than AZE-treated patients as measured by overall RQLQ score (mean ± SD 2.91 ± 1.08 vs. 2.05 ± 1.15) and EQ-5D score (mean ± SD 87.4 ± 10.3 vs. 83.0 ± 12.8). MP-AzeFlu was well tolerated. CONCLUSIONS: MP-AzeFlu was superior to AZE in reducing moderate-to-severe SAR symptoms, providing earlier and more complete symptom relief.
SN - 1423-0097
UR - https://www.unboundmedicine.com/medline/citation/30677766/Efficacy_of_a_Novel_Intranasal_Formulation_of_Azelastine_Hydrochloride_and_Fluticasone_Propionate_Delivered_in_a_Single_Spray_for_the_Treatment_of_Seasonal_Allergic_Rhinitis:_Results_from_Russia_
L2 - https://www.karger.com?DOI=10.1159/000494507
DB - PRIME
DP - Unbound Medicine
ER -